Nocturnal oxyhaemoglobin desaturation and plasminogen activator inhibitor type-1

被引:0
|
作者
Pencic, B. [1 ]
Dekleva, M. [1 ]
Celic, V. [1 ]
Caparevic, Z. [1 ]
Kostic, N. [1 ]
Grdinic, A. [1 ]
机构
[1] Univ Clin Ctr, Belgrade, Serbia
关键词
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The aim of this study was to evaluate the relation between plasminogen activator inhibitor type-1(PAI-1) and nocturnal oxyhaemoglobin desaturation in hypertensive patients (pts).We included 40 hypertensive pts free of coronary artery disease; heart failure; pulmonary diseases. All pts underwent overnight finger pulse oximeter. Oxyhaemoglobin desaturation > 3% was considered significant. Pts with oxyhaemoglobin desaturation index (ODI) >= 5/h consisted group I and pts with ODI < 5/h entered group II. PAI-l(U/mL) levels were measured before and immediately after bicycle exercise test. There were 18 pts in group I (age 53.31 +/- 8.48; 10 male) and 22 pts in group II (age 52.48 +/- 7.32;14 male). Groups were similar in demographic and clinical characteristics. PAI-l levels were significantly higher in group I compared to group II before (3.28 +/- 1.0 U/mL vs 2.36 +/- 0.71U/mL, p=0.041) as well as after exercise (3.18 +/- 0.78 U/mL vs 2.27 +/- 0.46 U/mL, p=0.009). It could be concluded that nocturnal oxyhaemglobin desaturation > 3% is significantly associated with higher PAI-1 levels before and after exercise test in hypertensive patients.
引用
收藏
页码:265 / 268
页数:4
相关论文
共 50 条
  • [41] Expression of type-1 kidney plasminogen activator inhibitor in the of diabetic rat models
    Hagiwara, H
    Kaizu, K
    Uriu, K
    Noguchi, T
    Takagi, I
    Qie, YL
    Seki, T
    Ariga, T
    THROMBOSIS RESEARCH, 2003, 111 (4-5) : 301 - 309
  • [42] Impact of statins on modulation by insulin of expression of plasminogen activator inhibitor type-1
    Sato, Yuki
    Dong, Jie
    Imagawa, Shogo
    Ishimori, Naoki
    Furumoto, Tomoo
    Tsutsui, Hiroyuki
    Sobel, Burton E.
    Fujii, Satoshi
    CORONARY ARTERY DISEASE, 2008, 19 (05) : 355 - 361
  • [43] Plasminogen activator inhibitor type-1 in cardiovascular disease - Status report 2001
    Huber, K
    Christ, G
    Wojta, J
    Gulba, D
    THROMBOSIS RESEARCH, 2001, 103 : S7 - S19
  • [44] INHIBITION OF ENDOTHELIAL EXPRESSION OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR BY GEMFIBROZIL
    FUJII, S
    SOBEL, BE
    CIRCULATION, 1992, 86 (04) : 741 - 741
  • [45] PLASMINOGEN-ACTIVATOR INHIBITOR (TYPE-1) IN RAT ADRENAL-MEDULLA
    ERIKSEN, J
    KRISTENSEN, P
    PYKE, C
    DANO, K
    HISTOCHEMISTRY, 1989, 92 (05) : 377 - 383
  • [46] EXPRESSION OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR IN CHRONIC PULMONARY THROMBOEMBOLI
    LANG, IM
    MARSH, JJ
    OLMAN, MA
    MOSER, KM
    LOSKUTOFF, DJ
    SCHLEEF, RR
    CIRCULATION, 1994, 89 (06) : 2715 - 2721
  • [47] Modulation of type-1 plasminogen activator inhibitor-induced vitronectin multimerization
    Seiffert, D
    FIBRINOLYSIS & PROTEOLYSIS, 1997, 11 (5-6): : 231 - 237
  • [48] CDNA FOR BOVINE TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1)
    MIMURO, J
    SAWDEY, M
    HATTORI, M
    LUSKUTOFF, DJ
    NUCLEIC ACIDS RESEARCH, 1989, 17 (21) : 8872 - 8872
  • [49] THE ROLE OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR IN FAILURE OF THROMBOLYTIC THERAPY WITH RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR
    HUBER, K
    BECKMANN, R
    RAUSCHA, F
    PROBST, P
    KAINDL, F
    BINDER, BR
    ZEITSCHRIFT FUR KARDIOLOGIE, 1993, 82 : 195 - 200
  • [50] EPITHELIAL GLYCOPROTEIN-330 MEDIATES ENDOCYTOSIS OF PLASMINOGEN ACTIVATOR-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 COMPLEXES
    MOESTRUP, SK
    NIELSEN, S
    ANDREASEN, P
    JORGENSEN, KE
    NYKJAER, A
    ROIGAARD, H
    GLIEMANN, J
    CHRISTENSEN, EI
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1993, 268 (22) : 16564 - 16570